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Summary  Angiogenic  cytokines  have  been  shown  to  inﬂuence  vessel  injury,  and  platelets
represent  a  disposable  circulating  pool  of  angiogenic  molecules.  In  the  present  study,  objectives
were to  determine  whether  clopidogrel  could  have  a  potential  effect  on  levels  of  circulating
biomarkers  of  angiogenesis  and  endothelial  activation.
We explored  28  healthy  white  male  volunteers  treated  for  7  days  with  clopidogrel  75  mg/day.
We quantiﬁed  angiogenic  growth  factors  that  have  been  shown  to  be  correlated  to  cardiovas-
cular risk  or  endothelial  progenitor  cell  mobilization  such  as  vascular  endothelial  growth  factor
(VEGF)-A  and  its  soluble  receptor  forms  VEGFR1  and  VEGFR2,  placenta  growth  factor,  and  stro-
mal cell-derived  factor-1.  We  also  quantiﬁed  soluble  E-selectin  and  von  Willebrand  factor  to
evaluate endothelial  activation.  Blood  samples  were  drawn  just  before  the  ﬁrst  clopidogrel
intake on  day  1,  and  after  the  last  dosing  (day  7).
As expected,  we  observed  a  decrease  in  platelet  reactivity  in  response  to  clopidogrel,  con-
ﬁrmed by  vasodilator-stimulated  phosphoprotein  phosphorylation  assay.  However,  the  7-day
t  signiﬁcantly  modify  the  levels  of  the  selected  angiogenic  factorsintake of  clopidogrel  did  no
or biomarkers  of  endothelial  activation.
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Introduction
Platelet  adhesion,  activation,  and  aggregation  are  consid-
ered  as  the  initial  steps  in  thrombus  formation.  The  key
role  of  platelet  activation  in  atherothrombosis  and  resteno-
sis  after  percutaneous  coronary  intervention  (PCI)  [1,2]  is
underlined  by  the  efﬁcacy  of  antiplatelet  therapy  with
aspirin  and  clopidogrel  in  these  indications  [3,4]. Once
recruited  to  the  proximity  of  the  vessel  wall,  platelets  may
release  large  amounts  of  either  proinﬂammatory  molecules
or  angiogenic  growth  factors,  such  as  vascular  endothe-
lial  growth  factor  (VEGF)  or  stromal  cell-derived  factor
(SDF)-1  [5,6]. Moreover,  the  treatment  of  human  platelets
with  different  agonists  results  in  the  release  of  pro-  or
anti-angiogenic  containing  granules  [7].  Thus,  separate
packaging  of  angiogenesis  regulators  might  be  differently
modulated  by  antiplatelet  agents.  These  pharmacologi-
cal  molecules  targeting  platelet  activation  pathways  might
modify  the  mechanisms  by  which  platelets  can  locally
stimulate  or  inhibit  angiogenesis  [8].  Beside  their  role  in  lim-
iting  platelet  activation,  there  is  increasing  evidence  that
antiplatelet  agents  also  exert  anti-inﬂammatory  actions.
Indeed,  reduced  levels  of  CD40  ligand,  C-reactive  protein  or
P-selectin  have  been  found  in  patients  taking  antiplatelet
agents,  either  aspirin  or  clopidogrel  [9,10].
Clopidogrel  targets  the  ADP  P2Y12  receptor  on  platelets,
responsible  for  platelet  irreversible  aggregation  in  response
to  ADP.  However,  recent  data  suggest  further  roles  for  this
receptor.  First,  platelet  P2Y12  receptor  has  been  shown  to
inﬂuence  vessel  wall  responses  to  injury  and  thrombosis
[11,12].  Second,  P2Y12  has  been  evidenced  on  other  cell
types,  including  smooth  muscle  cells  [13]  and  endothelial
cells  [14,15].  A  role  for  P2Y12  has  been  recently  suggested  in
endothelial  function  with  the  demonstration  of  an  improve-
ment  of  endothelial  dysfunction  in  patients  with  stable
coronary  artery  disease  after  a  loading  dose  of  clopido-
grel  [16]  and  an  improvement  in  endothelial  nitric  oxide
bioavailability  in  patients  with  symptomatic  coronary  artery
disease,  suggesting  that  P2Y12  blockade  may  have  vasopro-
tective  effects  [17]. Finally,  P2Y12  blockade  by  clopidogrel
has  been  recently  found  to  decrease  circulating  endothelial
cells  (CEC)  levels  in  type  2  diabetes  [18]  and  to  prevent  their
release  after  PCI  [19].
Angiogenic  cytokines  have  been  shown  to  inﬂuence  ves-
sel  injury,  and  platelets  represent  a  disposable  circulating
pool  of  angiogenic  molecules.  We  hypothesized  that  clopi-
dogrel  could  have  a  potential  effect  on  physiological  levels
of  circulating  biomarkers  of  angiogenesis  and  endothelial
activation.
MethodsSubjects  and  study  protocol
To  be  free  from  hormonal  status  or  of  any  interference
of  angiogenic  cytokines  released  by  circulating  activated
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g  angiogenic  factor  level  in  healthy  subjects  is  not  driven  by
activation  and  clopidogrel  does  not  modify  in  a  signiﬁcant  way
ology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
latelets  in  patients  with  cardiovascular  diseases,  we
xplored  only  healthy  male  volunteers.  Twenty  eight  sub-
ects  aged  18—35  years  were  enrolled,  based  on  the
ollowing  criteria:  nonsmokers,  normal  physical  and  labo-
atory  results  (including  white  and  red  blood  cell  count,
iver  enzymes,  blood  glucose,  serum  creatinine,  prothrom-
in  time,  activated  partial  thromboplastin  time,  and  plasma
brinogen,  results  reported  in  Table  1).  The  subjects  were
sked  to  come  to  the  Clinical  Investigations  Center  every
ay  at  9  AM,  where  they  were  given  a  standard  dose  of
lopidogrel  75  mg  once  daily  for  7  consecutive  days  in  the
resence  of  medical  staff.  Blood  samples  were  drawn  just
efore  the  ﬁrst  clopidogrel  intake  on  day  1,  and  after  the
ast  dosing  (day  7).  The  objective  of  this  study  was  to  evalu-
te  the  response  to  clopidogrel  according  to  P2Y12  genotype
H1H1  and  H1H2  haplotypes)  as  detailed  elsewhere  [20,21].
he  sample  size  was  calculated  with  the  hypothesis  of  a
5%  difference  in  aggregation  between  groups  with  a  risk
lpha  of  5%  and  beta  20%.  The  present  study  was  further
erformed  given  that  no  difference  in  platelet  response
o  clopidogrel  was  noticed  according  to  the  genotype  and
hat  baseline  angiogenic  growth  factor  levels  did  not  differ
etween  groups.
The  study  was  approved  by  the  ‘‘Comité  de  Protec-
ion  des  Personnes  se  Prêtant  à  la  Recherche  Biomedicale’’
Paris-Cochin,  France),  and  all  the  subjects  gave  their  writ-
en  informed  consent  to  participate,  in  accordance  with  the
eclaration  of  Helsinki.
harmacodynamic  evaluation
e  assessed  the  level  of  phosphorylated  vasodilator-
timulated  phosphoprotein  (VASP),  a  good  index  of  P2Y12
ctivity  [21,22]. P2Y12  is  a  Gi-coupled  receptor  whose  acti-
ation  reduces  the  platelet  cyclic  adenosine  monophosphate
cAMP)  level  by  inhibiting  adenyl  cyclase.  The  decrease  in
AMP  production  leads  to  a  reduction  in  the  activation  of
peciﬁc  protein  kinases,  which  can  no  longer  phosphory-
ate  VASP.  The  level  of  phosphorylated  VASP,  which  can  be
easured  by  ﬂow  cytometry,  is  thus  a good  index  of  inhibi-
ion  of  the  ADP-P2Y12  interaction  by  clopidogrel.  VASP  was
easured  in  whole  blood  on  days  1  (baseline)  and  7  of  clopi-
ogrel  intake,  using  a  ﬂow  cytometric  assay  (Platelet  VASP;
iagnostica  Stago,  Biocytex,  Asnières,  France)  adapted  to
 Cy-Flow  apparatus  (Partec,  Münster,  Germany).  Results
ere  expressed  as  a  platelet  reactivity  index  (PRI,  %)  calcu-
ated  from  the  mean  ﬂuorescence  intensity  (MFI)  of  samples
ncubated  with  prostaglandin  (PGE1)  alone  or  with  both
GE1 and  ADP  simultaneously,  using  the  following  formula:
(MFIPGE1 −  MFIPGE1+ADP)/MFIPGE1)  ×  100.
LISA  assayse  quantiﬁed  angiogenic  growth  factors  that  have  been
hown  to  be  correlated  to  cardiovascular  risk  or  endothelial
32  D.M.  Smadja  et  al.
Table  1  Biological  characteristics  of  the  subjects.
N  =  28
Blood  leukocyte  count
(giga/L)
5.3  (3.2—8.1)
Red blood  cell  count  (tera/L)  4.7  (4.2—5.3)
Hemoglobin  (g/dL)  14.2  (13.2—15.4)
Hematocrit  (%)  42  (39—45)
Blood platelet  count  (giga/L)  216  (153—321)
Fasting  blood  glucose
(mmol/L)
4.8  (3.4—5.4)
Aspartate  transaminase
(IU/L)
19  (11—44)
Alanine  transaminase  (IU/L)  21  (12—50)
Alkaline  phosphatase  (IU/L) 52  (31—82)
Gamma-glutamyltransferase
(IU/L)
19 (5—40)
Serum  creatinine  (mol/L)  83  (63—111)
Plasma  total  protein  (g/L)  90  (73—100)
Activated  partial
thromboplastin  time  (APTT
ratio)
1.08  (0.9—1.2)
Fibrinogen  (g/L) 2.2  (1.9—3.5)
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Figure  1  Vasodilator-stimulated  phosphoprotein  (VASP)  phos-
p
a
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of  each  parameter  and  VASP  PRI.
These  results  show  that:  (1)  circulating  angiogenic  fac-
tor  level  is  not  driven  by  P2Y12  platelet  receptor-induced
Figure  2  Comparison  of  vascular  endothelial  growth  factor
(VEGF),  stromal  cell-derived  factor  (SDF)-1,  placenta  growth
factor  (PlGF),  and  soluble  receptors  of  VEGF  (sVEGFR-1  and
sVEGFR-2)  levels  in  28  healthy  male  volunteers  after  7  days
of clopidogrel.  The  median  VEGF  value  [range]  was  12.1  pg/mL
[3.3—207.5]  at  day  1  and  10.6  pg/mL  [2.3—23.3]  after  7  days  of
clopidogrel.  The  median  SDF-1  value  (range)  was  2015  pg/mL
[1373—2690]  at  day  1  and  1910  pg/mL  [1435—2690]  after
7 days  of  clopidogrel.  The  median  PlGF  value  (range)  was
4.6 pg/mL  [1.5—9.9]  at  day  1  and  5.2  pg/mL  [2.6—8.4]  after  7
days of  clopidogrel.  The  median  sVEGFR-1  value  (range)  was
84.7 pg/mL  [49.9—1334]  at  day  1  and  92.4  pg/mL  [50.6—237.4]Data are presented as median values (range).
rogenitor  cell  mobilization  such  as  VEGF-A  and  its  soluble
eceptor  forms,  placenta  growth  factor  (PlGF),  and  SDF-1.
e  also  quantiﬁed  soluble  E-selectin  and  von  Willebrand
actor  (VWF)  as  a  reﬂection  of  endothelial  activation.  All
arkers  but  VWF  were  quantiﬁed  in  citrated  plasma  with
lisa  Quantikine  test  (R&D  Systems,  Lille,  France).  VWF
as  quantiﬁed  with  Asserachrom® VWF  Antigen  kit  (Stago,
ourtaboeuf,  France).
tatistical  analysis
tudent’s  paired  t  test  was  used  to  compare  endothe-
ial  biomarkers  before  and  after  clopidogrel  treatment.
tatView  software  was  used  for  all  statistical  analyses,  and
-values  below  0.05  were  considered  to  denote  signiﬁcant
ifferences.
esults
ubjects  were  given  clopidogrel  75  mg  once  daily  during  7
ays,  with  no  loading  dose.  Pharmacodynamic  response  to
lopidogrel  was  assessed  by  the  VASP  assay  (as  PRI).  On  day
,  the  PRI  had  signiﬁcantly  decreased  compared  to  baseline,
rom  72  ±  6%  to  45  ±  17%  (p  <  0.001,  Fig.  1).
Baseline  plasma  levels  of  VEGF,  PlGF,  SDF1,  sVEGFR1,
VEGFR2,  sE-selectin,  and  VWF  were  all  within  the  normal
ange  reported  by  our  group  and  others  [23]. As  shown  in
ig.  2,  a  7-day  intake  of  clopidogrel  did  not  signiﬁcantly
odify  the  levels  of  the  selected  angiogenic  factors  (VEGF,
 =  0.15;  PlGF,  p  =  0.78;  SDF1,  p  =  0.30),  angiogenic  recep-
or  soluble  forms  (sVEGFR1,  p  =  0.66;  sVEGFR2,  p  =  0.88),  nor
iomarkers  of  endothelial  activation  (E-selectin,  p  =  0.65;
WF,  p  =  0.64;  Fig.  3).  Moreover,  no  correlation  was  found
a
(
[horylation  level  (platelet  reactivity  index,  %)  at  baseline  and
fter a  7-day  clopidogrel  75  mg  intake.
etween  the  difference  between  day  7  and  baseline  valuefter 7  days  of  clopidogrel.  The  median  sVEGFR-2  value
range)  was  1673.5  pg/mL  [1074—2394]  at  day  1  and  1595  pg/mL
1311—2080]  after  7  days  of  clopidogrel.
Effect  of  clopidogrel  on  circulating  biomarkers  of  angiogenesis  a
Figure  3  Comparison  of  sE-selectin  and  von  Willebrand  factor
(VWF)  levels  in  28  healthy  male  volunteers  after  7  days  of  clopi-
dogrel.  The  median  sE-selectin  value  (range)  was  26.3  ng/mL
[12.1—44.8]  at  day  1  and  268.6  ng/mL  [100—45.6]  after  7  days
of clopidogrel.  The  median  VWF  antigen  value  (range)  was  69.2%
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i[28.9—134.9]  at  day  1  and  70.0%  [35.6—117.2]  after  7  days  of
clopidogrel.
activation,  at  least  in  healthy  volunteers;  and  (2)  clopido-
grel  does  not  modify  in  a  signiﬁcant  way  the  endothelial
activation  level.
Discussion
To  our  knowledge,  this  is  the  ﬁrst  study  exploring  the  effect
of  clopidogrel  on  angiogenic  and  endothelial  activation  sol-
uble  biomarkers.Clopidogrel  is  widely  used  in  patients  with
coronary  artery  disease  (CAD)  and/or  PCI  to  reduce  the
risk  of  thrombotic  events  [24—29]. The  VASP  index  is  the
most  speciﬁc  platelet  assay  to  evaluate  P2Y12  ADP  recep-
tor  blockade  and  is  not  inﬂuenced  by  other  antiplatelet
agents  or  anticoagulants  [22]. VASP  index  was  shown  to
have  a  high  negative  predictive  value  for  major  adverse
cardiovascular  events  [30,31].  Despite  the  large  well-known
inter-individual  variability  in  the  response  to  clopidogrel,  we
did  not  ﬁnd  any  modiﬁcation  in  angiogenic  molecule  levels
upon  clopidogrel  treatment  and  no  correlation  according  to
P2Y12  inhibition,  as  assessed  by  the  VASP  index.  Identical
results  were  obtained  with  the  level  of  10  M  ADP-induced
platelet  aggregation  inhibition  (data  not  shown).
Using  VASP  index,  optimal  clopidogrel  responsiveness  was
recently  found  associated  with  reduced  CEC  elevation  fol-
lowing  PCI  [19]. Increased  levels  of  CEC  have  been  identiﬁed
across  a  broad  spectrum  of  cardiovascular  [32]  and  pul-
monary  diseases  [33,34]  and  have  been  linked  to  the  clinical
severity,  as  well  as  to  the  clinical  outcomes  of  CAD  [32]. Sev-
eral  studies  have  highlighted  the  interest  of  CEC  count  in
the  early  evaluation  of  endothelial  dysfunction  in  patients
undergoing  PCI  [35—37]. ADP  receptor  P2Y12  blockade  was
shown  to  independently  predict  CEC  level,  demonstrating
a  protective  effect  of  clopidogrel-dependent  inhibition  of
platelet  reactivity  on  endothelial  damage  during  PCI.  The
a
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echanisms  underlying  the  protection  of  the  endothelium
y  clopidogrel  remain  to  be  fully  elucidated,  in  particular  by
istinguishing  speciﬁc  endothelial  protection  in  PCI  or  angio-
enic  modiﬁcation  whatever  the  clinical  context.  Moreover,
ne  of  the  main  questions  remains:  is  the  endothelial  pro-
ection  dependent  on  endothelium—platelet  interactions?
Indeed,  ﬁndings  from  animal  models  and  in  vitro  studies
ave  identiﬁed  platelet-independent  effects  of  thienopy-
idines  on  vascular  cells.  A  modulation  of  vasoconstrictors
fter  intravenous  administration  of  clopidogrel  [38]  and  an
ncrease  in  nitric  oxide  production  in  endothelial  cells  incu-
ated  with  thienopyridines  have  been  previously  described
39].  Moreover,  previous  work  showed  that  ADP  increased
uman  endothelial  cell  migration,  thus  potentially  con-
ributing  to  reendothelialization  and  angiogenesis  after
ascular  injury,  by  activating  P2Y1  receptor  mediated
itogen-activate  protein  kinase  pathway,  but  not  via  P2Y12
40]. In  platelets,  P2Y1  is  known  to  be  involved  in  shape
hange  and  in  reversible  platelet  aggregation,  contrast-
ng  with  its  potential  important  function  in  endothelial
ells.  Our  results  could  add  relevance  to  the  non  signif-
cant  implication  of  P2Y12  in  endothelial  cell  biology,  in
ine  with  clopidogrel  speciﬁcity  against  P2Y12.  In  addition,
latelet  release  generated  by  activation  with  ADP  has  been
ecently  shown  to  promote  migration  and  formation  of  cap-
llary  structures  by  human  umbilical  vein  endothelial  cells
n  in  vitro  angiogenesis  models  [41]. Thus,  the  inhibition  of
2Y12  activation  by  clopidogrel  might  interfere  with  circu-
ating  VEGF  or  other  growth  factors  released  by  platelets.
owever,  no  modiﬁcation  was  observed  in  our  study.
One  limitation  of  this  work  is  the  small  sample  size
f  our  population  that  may  not  allow  detection  of  minor
ifferences.  However,  the  absence  of  any  trend  whatever
he  biomarker  tested  argues  against  a  major  effect.  The
ffect  of  clopidogrel  on  endothelial  function  remains  to  be
xplored  in  cardiovascular  patients,  in  which  atherothrom-
osis  mediators,  such  as  nicotine,  may  increase  P2Y12
ndothelial  expression  level  [14]. Moreover,  short  or  long-
erm  clopidogrel  treatment  has  been  proposed  to  act  like
n  anti-inﬂammatory  drug  [42—44], and  P2Y12  receptor  has
een  shown  to  be  required  for  proinﬂammatory  actions  [45].
ecause  inﬂammation  and  angiogenic  markers  have  been
ound  linked  in  different  clinical  settings  and  in  endothe-
ial  progenitor  cell  mobilization,  a  modulation  of  angiogenic
arkers  could  be  one  of  the  effects  of  clopidogrel.  In  our
etting,  i.e.  physiological  situation,  we  showed  that  P2Y12  is
ot  involved  in  angiogenesis  homeostasis,  with  the  limitation
f  the  parameters  studied.
Another  limitation  of  our  study  is  the  dose  of  clopidogrel
hat  could  be  insufﬁcient  to  inﬂuence  the  level  of  angio-
enic  soluble  factors.  However,  the  antiplatelet  effect  of
lopidogrel  has  been  demonstrated  at  the  early  beginning
o  prevent  ischemic  events  in  patients  with  atherosclerosis
46]  at  a  recommended  dose  of  75  mg/day.  The  signiﬁ-
ant  decrease  of  VASP  index  shown  in  Fig.  1  conﬁrms  that
lopidogrel  75  mg/day  modiﬁes  platelet  functions  but  we
ave  no  idea  of  the  required  dose  to  modify  platelet-
ndependent  functions  of  clopidogrel.  Thereby,  angiogenic
nd  endothelial  markers  should  also  be  explored  following
lopidogrel  loading  dose  or  with  maintenance  doses  higher
han  75  mg/day,  and  particularly  with  the  new  more  potent
ntiplatelet  agents  (prasugrel,  ticagrelor,  anti-PAR1).
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In  conclusion,  the  receptor  P2Y12  inhibition  by  clopido-
rel  is  not  associated  with  a  modiﬁcation  of  physiological
evels  of  endothelial/angiogenesis  biomarkers  in  healthy
ubjects.  It  remains  to  be  determined  how  clopidogrel  P2Y12
lockade  on  cells  other  than  platelets  could  have  con-
equences  in  atherothrombosis  and/or  vessel  injury  and
emodeling.
cknowledgments
his  work  was  supported  by  research  grants  from  the  Pro-
ramme  Hospitalier  de  Recherche  Clinique  (Ministère  chargé
e  la  Santé,  PHRC  RBM  02-58,  sponsor:  INSERM).  We  thank
he  nursing  staff  of  Georges  Pompidou  European  Hospital
linical  Investigation  Center  and  Leducq  TransAtlantic  Net-
ork  of  Excellence  on  Atherothrombosis  Research  (Grant
4CVD01).
eferences
[1] Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new
mechanisms and clinical targets. Nat Med 2002;8:1257—62.
[2] Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR,
Arepally GM, French PA, Dauerman HL, Becker RC, 2009
Platelet Colloquium Participants. Platelet functions beyond
hemostasis. Thromb Haemost 2009;7:1759—66.
[3] Gachet C. P2 receptors, platelet function and pharmacological
implications. Thromb Haemost 2008;99:466—72.
[4] Gachet C. ADP receptors of platelets and their inhibition.
Thromb Haemost 2001;86:222—32.
[5] Stellos K, Gawaz M. Platelet interaction with progenitor cells:
potential implications for regenerative medicine. Thromb
Haemost 2007;98:922—9.
[6] Stellos K, Gawaz M. Platelets and stromal cell-derived factor-
1 in progenitor cell recruitment. Semin Thromb Hemost
2007;33:159—64.
[7] Italiano Jr JE, Richardson JL, Patel-Hett S, Battinelli E,
Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL.
Angiogenesis is regulated by a novel mechanism: pro-
and antiangiogenic proteins are organized into separate
platelet alpha granules and differentially released. Blood
2008;111:1227—33.
[8] Jain S, Harris J, Ware J. Platelets: linking hemostasis and can-
cer. Arterioscler Thromb Vasc Biol 2010;30:2362—7.
[9] Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF.
Clinical evidence for anti-inﬂammatory effects of antiplatelet
therapy in patients with atherothrombotic disease. Vasc Med
2007;12:113—22.
10] Yeh ET, Khan BV. The potential role of antiplatelet agents
in modulating inﬂammatory markers in atherothrombosis. J
Thromb Haemost 2006;4:2308—16.
11] Evans DJ, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM,
Jetha K, Norman KE, Francis SE, Storey RF. Platelet P2Y(12)
receptor inﬂuences the vessel wall response to arterial injury
and thrombosis. Circulation 2009;119:116—22.
12] Rauch BH, Rosenkranz AC, Ermler S, Bohm A, Driessen J, Fis-
cher JW,  Sugidachi A, Jakubowski JA, Schrör K. Regulation of
functionally active P2Y12 ADP receptors by thrombin in human
smooth muscle cells and the presence of P2Y12 in carotid artery
lesions. Arterioscler Thromb Vasc Biol 2010;30:2434—42.
13] Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R,
Gudbjartsson T, Erlinge D. ADP receptor P2Y12 is expressed
in vascular smooth muscle cells and stimulates contrac-
tion in human blood vessels. Arterioscler Thromb Vasc Biol
2004;24:1810—5.
[D.M.  Smadja  et  al.
14] Shanker G, Kontos JL, Eckman DM, Wesley-Farrington D,
Sane DC. Nicotine upregulates the expression of P2Y12 on
vascular cells and megakaryoblasts. J Thromb Thrombolysis
2006;22:213—20.
15] Simon J, Filippov AK, Goransson S, Wong YH, Frelin C, Michel
AD, Brown DA, Barnard EA. Characterization and channel cou-
pling of the P2Y(12) nucleotide receptor of brain capillary
endothelial cells. J Biol Chem 2002;277:31390—400.
16] Warnholtz A, Ostad MA, Velich N, Trautmann C, Schinzel
R, Walter U, Munzel T. A single loading dose of clopi-
dogrel causes dose-dependent improvement of endothelial
dysfunction in patients with stable coronary artery disease:
results of a double-blind, randomized study. Atherosclerosis
2008;196:689—95.
17] Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K,
Ortak M, Tschentscher P, Meinertz T, Böger R, Baldus S. Clopido-
grel improves systemic endothelial nitric oxide bioavailability
in patients with coronary artery disease: evidence for antiox-
idant and antiinﬂammatory effects. Arterioscler Thromb Vasc
Biol 2006;26:1648—52.
18] McClung JA, Kruger AL, Ferraris A, Vanella L, Tsenovoy P,
Weiss MB, Abraham NG. Usefulness of clopidogrel to pro-
tect against diabetes-induced vascular damage. Am J Cardiol
2010;105:1014—8.
19] Bonello L, Harhouri K, Sabatier F, Camoin-Jau L, Arnaud L,
Baumstarck-Barrau K, Ait-Mokhtar O, Roubille F, Piot C, Lesavre
N, Paganelli F, Dignat-George F. Level of adenosine diphosphate
receptor P2Y12 blockade during percutaneous coronary inter-
vention predicts the extent of endothelial injury, assessed by
circulating endothelial cell measurement. J Am Coll Cardiol
2010;56:1024—31.
20] Bura A, Bachelot-Loza C, Ali FD, Aiach M, Gaussem P. Role of the
P2Y12 gene polymorphism in platelet responsiveness to clopi-
dogrel in healthy subjects. J Thromb Haemost 2006;4:2096—7.
21] Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C,
Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss-of-
function polymorphism is a major determinant of clopidogrel
responsiveness in healthy subjects. Blood 2006;108:2244—7.
22] Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet
C. Flow cytometric analysis of intraplatelet VASP phosphory-
lation for the detection of clopidogrel resistance in patients
with ischemic cardiovascular diseases. J Thromb Haemost
2005;3:85—92.
23] Smadja D, Gaussem P, Roncal C, Fischer AM, Emmerich
J, Darnige L. Arterial and venous thrombosis is associated
with different angiogenic cytokine patterns in patients with
antiphospholipid syndrome. Lupus 2010;19:837—43.
24] Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ,
Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet
C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, et al.
Consensus and future directions on the deﬁnition of high on-
treatment platelet reactivity to adenosine diphosphate. J Am
Coll Cardiol 2010;56:919—33.
25] Hayashi F, Iijima R, Nakamura M, Sugi K. Safety and efﬁcacy of
clopidogrel treatment in Japanese patients undergoing drug-
eluting stent implantation. J Cardiol 2010;55:34—40.
26] Ogawa H, Hokimoto S, Kaikita K, Yamamoto K, Chitose T,
Ono T, Tsujita K. Current status and prospects of antiplatelet
therapy in percutaneous coronary intervention in Japan:
focus on adenosine diphosphate receptor inhibitors. J Cardiol
2011;58:6—17.
27] Uchida Y, Mori F, Ogawa H, Takagi A, Hagiwara N. Impact of anti-
coagulant therapy with dual antiplatelet therapy on prognosis
after treatment with drug-eluting coronary stents. J Cardiol
2010;55:362—9.
28] Park KH, Jeong MH, Lee MG, Ko JS, Sim DS, Yoon NS, Yoon HJ,
Hong YJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Kang
JC. What is the optimal duration of triple anti-platelet therapy
sis  a
[
[
[
[
[
[
[
[
[Effect  of  clopidogrel  on  circulating  biomarkers  of  angiogene
in patients with acute myocardial infarction undergoing drug-
eluting stent implantation? J Cardiol 2011;57:53—60.
[29] Nakagawa T, Hiasa Y, Hosokawa S, Minami T, Yano Y, Yoneda K,
Mizobe M, Murakami N, Tobetto Y, Chen H, Miyazaki S, Mahara
K, Ogura R, Miyajima H, Yuba K, et al. The potential bene-
ﬁts and risks of the use of dual antiplatelet therapy beyond 6
months following sirolimus-eluting stent implantation for low-
risk patients. J Cardiol 2011;57:283—9.
[30] Blindt R, Stellbrink K, de Taeye A, Muller R, Kiefer P, Yag-
mur E, Weber C, Kelm M, Hoffmann R. The signiﬁcance of
vasodilator-stimulated phosphoprotein for risk stratiﬁcation of
stent thrombosis. Thromb Haemost 2007;98:1329—34.
[31] Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol
J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilator-
stimulated phosphoprotein phosphorylation analysis prior to
percutaneous coronary intervention for exclusion of postproce-
dural major adverse cardiovascular events. J Thromb Haemost
2007;5:1630—6.
[32] Sabatier F, Camoin-Jau L, Anfosso F, Sampol J, Dignat-George
F. Circulating endothelial cells, microparticles and progenitors:
key players towards the deﬁnition of vascular competence. J
Cell Mol Med 2009;13:454—71.
[33] Smadja DM, Gaussem P, Mauge L, Israel-Biet D, Dignat-George F,
Peyrard S, Agnoletti G, Vouhé PR, Bonnet D, Lévy M. Circulating
endothelial cells: a new candidate biomarker of irreversible
pulmonary hypertension secondary to congenital heart disease.
Circulation 2009;119:374—81.
[34] Smadja DM, Mauge L, Sanchez O, Silvestre JS, Guerin C, Godier
A, Henno P, Gaussem P, Israël-Biet D. Distinct patterns of circu-
lating endothelial cells in pulmonary hypertension. Eur Respir
J 2010;36:1284—93.
[35] Boos CJ, Balakrishnan B, Jessani S, Blann AD, Lip GY. Effects
of percutaneous coronary intervention on peripheral venous
blood circulating endothelial cells and plasma indices of
endothelial damage/dysfunction. Chest 2007;132:1920—6.
[36] Bonello L, Basire A, Sabatier F, Paganelli F, Dignat-George
F. Endothelial injury induced by coronary angioplasty trig-
gers mobilization of endothelial progenitor cells in patients
[nd  endothelial  activation  35
with stable coronary artery disease. J Thromb Haemost
2006;4:979—81.
37] Hamasaki S, Tei C. Effect of coronary endothelial function on
outcomes in patients undergoing percutaneous coronary inter-
vention. J Cardiol 2011;57:231—8.
38] Yang LH, Fareed J. Vasomodulatory action of clopidogrel and
ticlopidine. Thromb Res 1997;86:479—91.
39] Ziemianin B, Olszanecki R, Uracz W,  Marcinkiewicz E, Gry-
glewski RJ. Thienopyridines: effects on cultured endothelial
cells. J Physiol Pharmacol 1999;50:597—604.
40] Shen J, DiCorleto PE. ADP stimulates human endothe-
lial cell migration via P2Y1 nucleotide receptor-mediated
mitogen-activated protein kinase pathways. Circ Res 2008;102:
448—56.
41] Battinelli EM, Markens BA, Italiano Jr JE. Release of angio-
genesis regulatory proteins from platelet alpha granules:
modulation of physiological and pathological angiogenesis.
Blood 2011;118:1359—69.
42] Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG,
Plow E, Topol EJ. Effect of clopidogrel pretreatment on inﬂam-
matory marker expression in patients undergoing percutaneous
coronary intervention. Am J Cardiol 2004;93:679—84.
43] Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel
with and without eptiﬁbatide on tumor necrosis factor-
alpha and C-reactive protein release after elective stenting:
results from the clear platelets 1b study. J Am Coll Cardiol
2006;48:2186—91.
44] Antonino MJ, Mahla E, Bliden KP, Tantry US, Gurbel PA. Effect
of long-term clopidogrel treatment on platelet function and
inﬂammation in patients undergoing coronary arterial stenting.
Am J Cardiol 2009;103:1546—50.
45] Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W, Jiang Y,
Kanaoka Y, Conley P, Boyce JA. Leukotriene E4-induced pul-
monary inﬂammation is mediated by the P2Y12 receptor. J Exp
Med 2009;206:2543—55.
46] CAPRIE. A randomised, blinded, trial of clopidogrel versus
aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE
Steering Committee. Lancet 1996;348:1329—39.
